Effects of Montmorency tart cherry juice consumption on cardiometabolic biomarkers in adults with metabolic syndrome: a randomized controlled pilot trial

Research output: Contribution to journalArticlepeer-review

Abstract

Greater than one-third of adults in the United States have metabolic syndrome (MetS), a cluster of risk factors highly associated with the development of cardiovascular diseases. Premature vascular dysfunction in MetS may lead to accelerated age-related atherogenesis and arterial stiffening, thereby increasing cardiovascular risk. Montmorency tart cherries (<i>Prunus cerasus</i> L.) are rich in bioactive compounds, such as anthocyanins, known to exert cardiovascular protective effects. Previous research suggests that tart cherry juice consumption may improve cardiovascular health. The objective of this study was to evaluate the effects of daily consumption of tart cherry juice on hemodynamics, arterial stiffness, and blood biomarkers of cardiovascular and metabolic health in men and women with MetS. In a randomized, single-blind, placebo-controlled, parallel-arm pilot clinical trial, 19 men and women 20 to 60 years of age with MetS consumed 240 mL of tart cherry juice (Tart Cherry; <i
Original languageEnglish
JournalJournal of Medicinal Food
DOIs
StatePublished - May 19 2020

Fingerprint

Dive into the research topics of 'Effects of Montmorency tart cherry juice consumption on cardiometabolic biomarkers in adults with metabolic syndrome: a randomized controlled pilot trial'. Together they form a unique fingerprint.

Cite this